Anandakumaran, P. N., Ayers, A. G., Muranski, P., Creusot, R. J., & Sia, S. K. (2022). Rapid video-based deep learning of cognate versus non-cognate T cell-dendritic cell interactions. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-021-04286-5

Ascierto, P. A., Agarwala, S. S., Blank, C., Caracò, C., Carvajal, R. D., Ernstoff, M. S., Ferrone, S., Fox, B. A., Gajewski, T. F., Garbe, C., Grob, J.-J., Hamid, O., Krogsgaard, M., Lo, R. S., Lund, A. W., Madonna, G., Michielin, O., Neyns, B., Osman, I., … Thurin, M. (2022). Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy). Journal of Translational Medicine, 20(1). https://doi.org/10.1186/s12967-022-03592-4

Cohen, A. O., Woo, S.-H., Zhang, J., Cho, J., Ruiz, M. E., Gong, J., Du, R., Yarygina, O., Jafri, D. Z., Bachelor, M. A., Finlayson, M. O., Soni, R. K., Hayden, M. S., & Owens, D. M. (2022). Tbc1d10c is a selective, constitutive suppressor of the CD8 T-cell anti-tumor response. OncoImmunology, 11(1). https://doi.org/10.1080/2162402x.2022.2141011

Liao, C.-Y., Johnson, B., Spira, A., Carbone, D., Henick, B., Overman, M., Polite, B., Roychowdhury, S., Mahipal, A., Ahn, D., Johnson, M., Schenk, D., Bae, K., Davis, M., Jooss, K., Ferguson, A., & Solomon, B. (2022). 660 Clinicopathologic characteristics of patients with metastatic colorectal cancer with molecular responses following treatment with an individualized neoantigen vaccine regimen. Regular and Young Investigator Award Abstracts, A691–A691. https://doi.org/10.1136/jitc-2022-sitc2022.0660

Liau, L. M., Ashkan, K., Brem, S., Campian, J., Trusheim, J., Iwamoto, F., Tran, D., Anstass, G., Cobbs, C., Heth, J., Salacz, M., D’Andre, S., Aiken, R., Moshel, Y., Nam, J., Pillainayagam, C., Wagner, S., Walter, K., Chaudary, R., … Bosch, M. (2022). CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL. Neuro-Oncology, 24(Supplement_7), vii66–vii66. https://doi.org/10.1093/neuonc/noac209.259

Wen, P. Y., Reardon, D. A., Forst, D., Lee, E., Daoud, T., Berthoud, T., Soare, C., Diaz-Mitoma, F., Anderson, D. E., Lassman, A., & Iwamoto, F. (2022). CTIM-14. COMPREHENSIVE BIOMARKER ANALYSIS OF RESPONDERS AND NON-RESPONDERS IN A PHASE IIA TRIAL OF A CMV VACCINE IMMUNOTHERAPEUTIC CANDIDATE (VBI-1901). Neuro-Oncology, 24(Supplement_7), vii62–vii62. https://doi.org/10.1093/neuonc/noac209.246

Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., Hernandez-Aya, L., Nathan, P., Hamid, O., Piulats, J. M., Rioth, M., Johnson, D. B., Luke, J. J., Espinosa, E., Leyvraz, S., Collins, L., Goodall, H. M., Ranade, K., Holland, C., Abdullah, S. E., … Sato, T. (2022). Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nature Medicine, 28(11), 2364–2373. https://doi.org/10.1038/s41591-022-02015-7

Peereboom, D., Lindsay, R., Badruddoja, M., Nabors, L. B., Kumthekar, P., Lieberman, F., Tran, D., Phuphanich, S., Schiff, D., Sherman, J., Butowski, N., Dunbar, E., Fink, K., Iwamoto, F., Moertel, C., Schulder, M., Walbert, T., Habboubi, N., Grzegorzewski, K., … Reardon, D. A. (2022). CTIM-29. PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GBM: IDENTIFICATION OF TREATMENT-INDUCED CD8+CD107A+ CD57+ PD-1- MEMORY T-CELLS THAT ARE ASSOCIATED WITH INCREASED SURVIVAL. Neuro-Oncology, 24(Supplement_7), vii67–vii67. https://doi.org/10.1093/neuonc/noac209.261

Hamid, O., Chiappori, A. A., Thompson, J. A., Doi, T., Hu-Lieskovan, S., Eskens, F. A. L. M., Ros, W., Diab, A., Spano, J.-P., Rizvi, N. A., Wasser, J. S., Angevin, E., Ott, P. A., Forgie, A., Yang, W., Guo, C., Chou, J., & El-Khoueiry, A. B. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(10), e005471. https://doi.org/10.1136/jitc-2022-005471

Dimitriou, F., Hassel, J. C., Orloff, M., Hughes, I., Kapiteijn, E., Mehmi, I., Montazeri, K., Johnson, D. B., Grover, P., Gerard, C. L., Simeone, E., Gaudy Marqueste, C., Cheng, P., Long, G. V., Carvajal, R. D., & Dummer, R. (2022). 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology, 33, S929. https://doi.org/10.1016/j.annonc.2022.07.958

Dimitriou, F., Namikawa, K., Reijers, I. L. M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K. C., … Long, G. V. (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33(9), 968–980. https://doi.org/10.1016/j.annonc.2022.06.004

Kyi, C. K., Spira, A., Carbone, D. P., Johnson, M. L., Henick, B. S., Johnson, B., Borghaei, H., Mahipal, A., Hecht, J. R., Catenacci, D., Liao, C.-Y., Shergill, A., Memmott, R., Presley, C., Jaroslavsky, J., Schenk, D., Jooss, K., Ferguson, A. R., & Goldman, J. W. (2022). 736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS). Annals of Oncology, 33, S880. https://doi.org/10.1016/j.annonc.2022.07.862

Khan, S., Lutzky, J., Shoushtari, A. N., Jeter, J., Marr, B., Olencki, T. E., Cebulla, C. M., Abdel-Rahman, M., Harbour, J. W., Sender, N., Nesson, A., Singh-Kandah, S., Hernandez, S., King, J., Katari, M. S., Dimapanat, L., Izard, S., Ambrosini, G., Surriga, O., … Carvajal, R. D. (2022). Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.976837

Wang, P. H., Washburn, R., Maniar, R., Mu, M., Ringham, O., Kratchmarov, R., Henick, B. S., & Reiner, S. L. (2022). Cutting Edge: Promoting T Cell Factor 1+ T Cell Self-Renewal to Improve Programmed Cell Death Protein 1 Blockade. The Journal of Immunology, 209(4), 660–664. https://doi.org/10.4049/jimmunol.2200317

Palmer, C. D., Rappaport, A. R., Davis, M. J., Hart, M. G., Scallan, C. D., Hong, S.-J., Gitlin, L., Kraemer, L. D., Kounlavouth, S., Yang, A., Smith, L., Schenk, D., Skoberne, M., Taquechel, K., Marrali, M., Jaroslavsky, J. R., Nganje, C. N., Maloney, E., Zhou, R., … Jooss, K. (2022). Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nature Medicine, 28(8), 1619–1629. https://doi.org/10.1038/s41591-022-01937-6

Lee, E. Y., Obradovic, A., Wang, E., & Christiano, A. M. (2022). 865 Single-cell protein activity inference analysis of full-thickness skin uncovers novel pathways and a rare Arg1+ macrophage population in AA. Journal of Investigative Dermatology, 142(8), S150. https://doi.org/10.1016/j.jid.2022.05.879

Rane, S., Hogan, T., Lee, E., Seddon, B., & Yates, A. J. (2022). Towards a unified model of naive T cell dynamics across the lifespan. ELife, 11. CLOCKSS. https://doi.org/10.7554/elife.78168

Carvajal, R. D., Nathan, P., Sacco, J. J., Orloff, M., Hernandez-Aya, L. F., Yang, J., Luke, J. J., Butler, M. O., Stanhope, S., Collins, L., McAlpine, C., Holland, C., Abdullah, S. E., & Sato, T. (2022). Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of Clinical Oncology, 40(17), 1939–1948. https://doi.org/10.1200/jco.21.01805

Stein, M. N., Fong, L., Tutrone, R., Mega, A., Lam, E. T., Parsi, M., Vangala, S., Gutierrez, A. A., & Haas, N. B. (2022). ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. The Oncologist, 27(6), 453–461. https://doi.org/10.1093/oncolo/oyac048

He, C., Malone, M. J., Wendel, B. S., Ma, K.-Y., Del Alcazar, D., Weiner, D. B., De Jager, P. L., Del Río-Estrada, P. M., Ablanedo-Terrazas, Y., Reyes-Terán, G., Su, L. F., & Jiang, N. (2022). Transcriptome and TCR Repertoire Measurements of CXCR3+ T Follicular Helper Cells Within HIV-Infected Human Lymph Nodes. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.859070

Abate-Shen, C., & Nunes de Almeida, F. (2022). Establishment of the LNCaP Cell Line – The Dawn of an Era for Prostate Cancer Research. Cancer Research, 82(9), 1689–1691. https://doi.org/10.1158/0008-5472.can-22-1065

Rashkovan, M., Albero, R., Gianni, F., Perez-Duran, P., Miller, H. I., Mackey, A. L., Paietta, E. M., Tallman, M. S., Rowe, J. M., Litzow, M. R., Wiernik, P. H., Luger, S., Sulis, M. L., Soni, R. K., & Ferrando, A. A. (2022). Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. Cancer Discovery, 12(3), 856–871. https://doi.org/10.1158/2159-8290.cd-21-0551

He, X., Zhou, S., Dolan, M., Shi, Y., Wang, J., Quinn, B., Jahagirdar, D., Huang, W.-C., Tsuji, M., Pili, R., Ito, F., Ortega, J., Abrams, S. I., Ebos, J. M. L., & Lovell, J. F. (2021). Immunization with short peptide particles reveals a functional CD8+T-cell neoepitope in a murine renal carcinoma model. Journal for ImmunoTherapy of Cancer, 9(12), e003101. https://doi.org/10.1136/jitc-2021-003101

Shoushtari, A. N., Khan, S., Komatsubara, K., Feun, L., Acquavella, N., Singh-Kandah, S., Negri, T., Nesson, A., Abbate, K., Cremers, S., Musi, E., Ambrosini, G., Lee, S., Schwartz, G. K., & Carvajal, R. D. (2021). A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers, 13(21), 5504. https://doi.org/10.3390/cancers13215504

Horwitz, S. M., Foran, J. M., Maris, M., Lue, J. K., Sawas, A., Okada, C., Feldman, T. A., Sokol, L., Mei, M., Flinn, I. W., Villa, D., Percival, M.-E. M., Jagadeesh, D., Savage, K. J., Akilov, O., Diefenbach, C. S., Kim, Y. H., Lin, G. H. Y., Catalano, T., … Ansell, S. M. (2021). Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 138(Supplement 1), 2448–2448. https://doi.org/10.1182/blood-2021-154490

Beylergil, V., Collins, L., Schwartz, L., Eche, T., Zhao, B., Carvajal, R., Abdullah, S., Beylergil, V., & Dercle, L. (2021). 819 Radiomic markers associated with clinical benefit in advanced uveal melanoma patients with radiographic progression on tebentafusp. Regular and Young Investigator Award Abstracts, A857–A857. https://doi.org/10.1136/jitc-2021-sitc2021.819

Gillison, M., Awad, M., Twardowski, P., Sukari, A., Johnson, M., Lackner, R., Stein, M., DeCillis, A., Hernandez, R., Price, J., Mancini, K., Shainheit, M., Santone, G., Shukor, S., Bicak, E., Vemulapalli, V., Tjon, E., Flechtner, J., Davis, T., & Cohen, R. (2021). 485 Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors. Regular and Young Investigator Award Abstracts, A515–A515. https://doi.org/10.1136/jitc-2021-sitc2021.485

Sacco, J., Carvajal, R., Butler, M., Shoushtari, A., Hassel, J., Ikeguchi, A., Hernandez-Aya, L., Nathan, P., Hamid, O., Piulats, J., Rioth, M., Johnson, D., Luke, J., Espinosa, E., Leyvraz, S., Holland, C., McCully, M., Abdullah, S., & Sato, T. (2021). 538 Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp. Regular and Young Investigator Award Abstracts, A568–A568. https://doi.org/10.1136/jitc-2021-sitc2021.538

Satish, T., Khan, S., Levin, M., Carvajal, R., & Yoon, A. J. (2021). Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission. Journal for ImmunoTherapy of Cancer, 9(10), e001219. https://doi.org/10.1136/jitc-2020-001219

Chaudhary, K. R., Halmos, B., Cheng, H., & Cheng, S. K. (2021). Bmi1 Resistance Pathway and Immune Checkpoint Blockade in Lung Cancer. International Journal of Radiation Oncology*Biology*Physics, 111(3), e432–e433. https://doi.org/10.1016/j.ijrobp.2021.07.1229

Park, S., Rong, L., Owczarek, T. B., Bernardo, M. D., Shoulson, R. L., Chua, C.-W., Kim, J. Y., Lankarani, A., Chakrapani, P., Syed, T., McKiernan, J. M., Solit, D. B., Shen, M. M., Al-Ahmadie, H. A., & Abate-Shen, C. (2021). Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression. Cancer Research, 81(20), 5161–5175. https://doi.org/10.1158/0008-5472.can-21-1254

Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., … Piperno-Neumann, S. (2021). Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. New England Journal of Medicine, 385(13), 1196–1206. https://doi.org/10.1056/nejmoa2103485

Roupakia, E., Chavdoula, E., Karpathiou, G., Vatsellas, G., Chatzopoulos, D., Mela, A., Gillette, J. M., Kriegsmann, K., Kriegsmann, M., Batistatou, A., Goussia, A., Marcu, K. B., Karteris, E., Klinakis, A., & Kolettas, E. (2021). Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition. Cancers, 13(17), 4302. https://doi.org/10.3390/cancers13174302